Endpoints News

Leo Pharma to license drug from Tanabe		Read in browser

Thank you for reading, dupa dupackia!

basic

UPGRADE

M Tue W Th F

18 August, 2026

Twenty new honorees join the 140-plus women Endpoints News has recognized for reshaping biopharma. How did they get there, and what's changed? Join us for exclusive interviews, in-depth profiles and a frank look at gender representation in the industry today. Register now.

news

Amylyx declares late-stage win with a GLP-1 antagonist in its post-ALS reset

Leo Pharma to license Tanabe’s rare disease drug for pain with sun exposure

Drugmakers voice support of US probe into Germany’s drug pricing plans

Aug 19

1:00 pm ET

From pilots to production: AI across R&D, safety, regulatory, and clinical

sponsored by Medable

One night, one room: the founders, scientists and investors behind the Endpoints 11, together in Boston this September. Reserve your spot now and save with the early bird rate.

ENDPOINTS PHARMA

Celcuity awaits FDA review for second factory to launch cancer drug

AstraZeneca touts separate late-stage lung cancer wins with Tagrisso, Enhertu

•

AstraZeneca cans late-stage bispecific trial after lung cancer setback

EyePoint’s bid to compete with Eylea falls flat

in case you missed it

Biotech's reverse merger renaissance poised to continue

Summit and Akeso's PD-1xVEGF bispecific got a new approval in China. It came with an unwelcome surprise

News Briefing

Lilly to pay up to $370M for OmniAb collab; Slate, Fulcrum forge reverse merger

Argenx declares Phase 3 win for Vyvgart Hytrulo in autoimmune myositis

Sandoz to license three biosimilar drugs from Shanghai Henlius Biotech

Does Amylyx believe in life after ALS? Co-CEOs Justin Klee and Joshua Cohen certainly think so, after the biotech reported late-stage data for a post-bariatric hypoglycemia drug that it got from Eiger. Get caught up with Max Gelman's coverage here.

Reynald Castaneda

Deputy Editor, Endpoints News

2029 Becker Drive; Lawrence, Kansas 66047 USA Privacy and deletion: help@endpointsnews.com